Apelin targets gut contraction to control glucose metabolism via the brain.

Files

hdl_103586.pdf (2.77 MB)
  (Published Version)

Date

2017

Authors

Fournel, A.
Drougard, A.
Duparc, T.
Marlin, A.
Brierley, S.
Castro, J.
Le-Gonidec, S.
Masri, B.
Colom, A.
Lucas, A.

Editors

Advisors

Journal Title

Journal ISSN

Volume Title

Type:

Journal article

Citation

Gut, 2017; 66(2):258-269

Statement of Responsibility

Audren Fournel, Anne Drougard, Thibaut Duparc, Alysson Marlin, Stuart M Brierley, Joel Castro, Sophie Le-Gonidec, Bernard Masri, André Colom, Alexandre Lucas, Perrine Rousset, Nicolas Cenac, Nathalie Vergnolle, Philippe Valet, Patrice D Cani, Claude Knauf

Conference Name

Abstract

Objective: The gut–brain axis is considered as a major regulatory checkpoint in the control of glucose homeostasis. The detection of nutrients and/or hormones in the duodenum informs the hypothalamus of the host’s nutritional state. This process may occur via hypothalamic neurons modulating central release of nitric oxide (NO), which in turn controls glucose entry into tissues. The enteric nervous system (ENS) modulates intestinal contractions in response to various stimuli, but the importance of this interaction in the control of glucose homeostasis via the brain is unknown. We studied whether apelin, a bioactive peptide present in the gut, regulates ENS-evoked contractions, thereby identifying a new physiological partner in the control of glucose utilisation via the hypothalamus. Design: We measured the effect of apelin on electrical and mechanical duodenal responses via telemetry probes and isotonic sensors in normal and obese/diabetic mice. Changes in hypothalamic NO release, in response to duodenal contraction modulated by apelin, were evaluated in real time with specific amperometric probes. Glucose utilisation in tissues was measured with orally administrated radiolabeled glucose. Results: In normal and obese/diabetic mice, glucose utilisation is improved by the decrease of ENS/contraction activities in response to apelin, which generates an increase in hypothalamic NO release. As a consequence, glucose entry is significantly increased in the muscle. Conclusions: Here, we identify a novel mode of communication between the intestine and the hypothalamus that controls glucose utilisation. Moreover, our data identified oral apelin administration as a novel potential target to treat metabolic disorders.

School/Discipline

Dissertation Note

Provenance

Description

Access Status

Rights

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/ licenses/by-nc/4.0/

License

Grant ID

Call number

Persistent link to this record